Latest Breaking News On - வெளியிடப்பட்டது பிப்ரவரி - Page 5 : comparemela.com

  (UPDATED) There is no difference in in-hospital outcomes or longer-term mortality between patients undergoing revascularization with either a durable-polymer DES or newer technology with a bioabsorbable polymer, according to the results of a retrospective analysis. Among more than 53,000 consecutive PCIs performed between 2015 and 2018 in Michigan, researchers found there was no difference in the risk of in-hospital mortality or stent thrombosis between patients who received the bioabsorbable-polymer everolimus-eluting stent (Synergy; Boston Scientific) and those treated with either the durable-polymer everolimus-eluting stent (Xience; Abbott Vascular) or the durable-polymer zotarolimus-eluting stent (Resolute; Medtronic). Importantly, at 2 years, there was also no significant difference in the risk of death between the stent groups.

New yorkUnited statesAnn arborAjay kirtaneNadia suttonDrug administration manufacturerPresbyterian hospital columbia university irving medical centerBoston scientificMd university of michigan cardiovascular centerAbbott vascularMichigan cardiovascular centerDrug administrationUser facility device experienceBlue cross shieldMichigan cardiovascular consortiumPublished february